. The clinical value of serum hyaluronic acid, procollagen III, N-terminal propeptide levels sST2 and cfDNA in children with severe pneumonia complicated by myocardial damage
serum hyaluronic acid, procollagen III, N-terminal propeptide levels sST2 and cfDNA in children
Abstract
【Abstract】Objective: The paper aimed to explore the clinical value of serum hyaluronic acid, procollagen III, N-terminal propeptide levels sST2 and cfDNA in guiding strategies for children with severe pneumonia complicated by myocardial damage. Methods: 140 children with severe pneumonia admitted to our hospital from May 2022 to April 2024 were clinically recruited as research subjects. According to whether the patients had myocardial damage, they were separated into a group with complicated myocardial damage (n=90) and a group without complicated myocardial damage. group (n=50). Children with myocardial damage were separated into a control group and an observation group. The control group (n=45) was given traditional care, and the observation group (n=45) was based on biomarkers (sST2 and cfDNA) levels guide the development of nursing strategies. Statistics of patients' general information based on clinical files. The patient's serum hyaluronic acid, procollagen III, N-terminal propeptide, sST2 and cfDNA levels were detected through biochemical analysis. Logistic regression was used to unpack the risk element affecting myocardial damage in children with pneumonia. The effectiveness of each biomarker in predicting severe pneumonia complicated by myocardial damage was analyzed based on the ROC curve. The levels of myocardial injury markers NT-proBNP, CK, CK-MB and C-reactive albumen in the control group and observation group were tested by enzyme-linked immunosorbent assay and enzyme activity assay. The clinical treatment effects of the two groups of patients were compared. Results: There was no distinguish in the general record of the two groups (P>0.05). The serum levels of hyaluronic acid, procollagen III, N-terminal propeptide, sST2 and cfDNA in invalids with complicated myocardial damage were higher than the group without myocardial damage (P<0.05). Hypoalbuminemia, age <3 years old, elevated levels of serum hyaluronic acid, procollagen III, N-terminal propeptide, sST2 and cfDNA were independent risk factors for myocardial damage in children with severe pneumonia (P<0.05). The AUC of serum hyaluronic acid in predicting myocardial injury in children with severe pneumonia was 0.70, with a sensitivity of 70% and a specificity of 65%. The predicted AUC of procollagen III was 0.68, the sensitivity was 65%, and the specificity was 70%. The predicted AUC of NT-proBNP was 0.78, the sensitivity was 75%, and the specificity was 80%. The predicted AUC of sST2 was 0.76, the sensitivity was 78.43%, and the specificity was 73.25%. The predicted AUC of cfDNA was 0.75, the sensitivity was 76.49%, and the specificity was 74.31%. The joint prediction AUC was 0.92, the sensitivity was 87.60%, and the specificity was 77%. The serum NT-proBNP, CK, CK-MB and C-reactive protein levels in the observation group were lower than control group (P<0.05).The clinical symptoms and effective rates of the observation group were higher than the control group (P<0.05). The ineffective proportion decreased than the control group (P<0.05). Conclusion: Serum hyaluronic acid, procollagen III, NT-proBNP, sST2 and cfDNA, as biomarkers, have significant value in predicting severe pneumonia complicated by myocardial damage.
References
[1] Li X, Guo X, Chang Y, et al. Analysis of alterations of serum inflammatory cyto-kines and fibrosis makers in patients with essential hypertension and left ventricular hypertrophy and the risk factors[J]. Am J Transl Res, 2022, 14:4097-4103.
[2] Chen Y, Zhao Y, Yuan L, et al. Periplaneta americana extract attenuates hepatic fibrosis progression by inhibiting collagen synthesis and regulating the TGF-β1/Smad signaling pathway[J]. Folia Histochem Cytobiol, 2023, 61:231-243.
[3] Tang X, Yang L, Zhang P, et al. Occult Hepatitis B Virus Infection and Liver Fi-brosis in Chinese Patients[J]. J Infect Dis, 2023, 228:1375-1384.
[4] Diemar SS, Dahl SS, West AS, et al. A Systematic Review of the Circadian Rhythm of Bone Markers in Blood[J]. Calcif Tissue Int, 2023, 112:126-147.
[5] He Y, Gu X, Yang Z, et al. Study on the mechanism underlying Trichosanthis peel injection-induced improvements in myocardial fibrosis markers in patients with chronic heart failure[J]. Clin Exp Pharmacol Physiol, 2024, 51:e13848.
[6] Moufarrej MN, Vorperian SK, Wong RJ, et al. Early prediction of preeclampsia in pregnancy with cell-free RNA[J]. Nature, 2022, 602:689-694.
[7] Su Y, Wang W, Liu F, et al. Blosozumab in the treatment of postmenopausal women with osteoporosis: a systematic review and meta-analysis[J]. Ann Palliat Med, 2022, 11:3203-3212.
[8] Li H, Xu X, Yi T, et al. Expression of chitinase-3-like protein 1 in different TCM syndromes and its correlation with liver fibrosis[J]. Ann Palliat Med, 2022, 11:217-224.
[9] Fan J, Li Y, Yan Q, et al. Higher serum sST2 is associated with increased left atri-al low-voltage areas and atrial fibrillation recurrence in patients undergoing radiof-requency ablation[J]. J Interv Card Electrophysiol, 2022, 64:733-742.
[10] Chen XF, Ji S. Sorafenib Attenuates Fibrotic Hepatic Injury Through Mediating Lysine Crotonylation[J]. Drug Des Devel Ther, 2022, 16:2133-2144.
[11] Huang Q, Zhang K, Li Y, et al. Auto- and Hetero-Catalytic Processing of the N-Terminal Propeptide Promotes the C-Terminal Fibronectin Type III Domain-Mediated Dimerization of a Thermostable Vpr-like Protease[J]. Appl Environ Micro-biol, 2022, 88:e0150322.
[12] Matsumoto T, Sone T, Soen S, et al. Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study[J]. J Clin Endocrinol Metab, 2022, 107:e4222-e4231.
[13] Malecki-Ketchell A. Acute coronary syndrome: role of the nurse in patient as-sessment and management[J]. Nurs Stand, 2022, 37:69-75.
[14] Wang S, Meng F, Li M, et al. Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer[J]. Am J Respir Crit Care Med, 2023, 207:1203-1213.
[15] Ćorović A, Wall C, Nus M, et al. Somatostatin Receptor PET/MR Imaging of Inflammation in Patients With Large Vessel Vasculitis and Atherosclerosis[J]. J Am Coll Cardiol, 2023, 81:336-354.
[16] Tokumoto M, Tokunaga S, Asada S, et al. Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism[J]. PLoS One, 2022, 17:e0279078.
[17] Gadelha MR, Gordon MB, Doknic M, et al. ACROBAT Edge: Safety and Effi-cacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly[J]. J Clin Endocrinol Metab, 2023, 108:e148-e159.
[18] Papadimitriou MA, Levis P, Kotronopoulos G, et al. Preoperative Cell-Free DNA (cfDNA) in Muscle-Invasive Bladder Cancer Treatment Outcome[J]. Clin Chem, 2023, 69:399-410.
[19] Vasikaran SD, Miura M, Pikner R, et al. Practical Considerations for the Clinical Application of Bone Turnover Markers in Osteoporosis[J]. Calcif Tissue Int, 2023, 112:148-157.
[20] Zhu Y, Pei L, Li N, et al. Preoperative sST2 levels relate to myocardial remodel-ing and cardiac function improvement after cardiac valve surgery[J]. ESC Heart Fail, 2024, 11:91-98.
[21] Chen Y, Zhao X, Liang L, et al. sST2 and Big ET-1 as Alternatives of Multi-Biomarkers Strategies for Prognosis Evaluation in Patients Hospitalized with Heart Failure[J]. Int J Gen Med, 2023, 16:5003-5016.
[22] Tang LJ, Li G, Eslam M, et al. N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD[J]. Hepatol Int, 2023, 17:190-201.
[23] Tominaga A, Wada K, Okazaki K, et al. Nonresponder Considerations for Ro-mosozumab Treatment[J]. Calcif Tissue Int, 2023, 113:157-165.
[24] Meng Q, Zhang M. Clinical Significance of Serum Collagen Type IV and Pro-collagen Type III N-Peptide Levels in Diagnosis and Differential Diagnosis of Lymphedema[J]. Lymphat Res Biol, 2023, 21:8-14.
[25] Esfahani MS, Hamilton EG, Mehrmohamadi M, et al. Inferring gene expression from cell-free DNA fragmentation profiles[J]. Nat Biotechnol, 2022, 40:585-597.
Copyright (c) 2024 Haoran Jia
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.